The algorithm of selection of the drug for the treatment of hypertension
Zadionchenko V.S.^1, Schikota A.M.^1, Yalymov A.A.^1, Shehyan G.G.^1, Timofeeva N.Y.^1, Oganezova L.G.^2,3 Terpigorev S.A.^3, Kabanova T.G.3, Nikishenkov A.M.<sup>3 

1</sup> Moscow State Medical Stomatological University named after A.I. Evdokimov
² Russian National Research Medical University named after N.I. Pirogov, Moscow
³ M.F. Vladimirskiy Moscow Regional Research and Clinical Institute

The article presents the algorithm of choosing the optimal antihypertensive drug for the treatment of hypertension in patients with high comorbidity (for example, in case of hypertension combination with chronic heart failure, diabetes, nephropathy, hypertrophy of the myocardium of the left ventricle of the heart). The article also gives a classification of arterial hypertension, describes the main groups of antihypertensive drugs with a description of their mechanism of action and possible side effects. Special attention is given to a non-pharmacological treatment: a psychological discharge, smoking cessation and limited alcohol consumption, physical activity and a balanced diet. The authors described in detail the hypotensive drug from the group of blockers of AT1-receptor of angiotensin II - candesartan (Giposart, Akrikhin company). The article presents the results of a multicenter randomized research of candesartan in patients with hypertension, nephropathy, with diabetes mellitus and heart failure.
The aim of using the algorithm is to achieve a protective effect in respect of targeted organs. The article provides the evidence base of efficiency and safety of candesartan. Candesartan has a good dose-dependent antihypertensive effect in all categories of patients with hypertension and can be recommended for a wider clinical use.

Key words: blocker AT1-receptor of angiotensin II, candesartan, Geocart, hypertension, nephropathy, heart failure, myocardial infarction
For citation: Zadionchenko V.S., Schikota A.M., Yalymov A.A. et al. The algorithm of selection of the drug for the treatment of hypertension // RMJ. 2017. № 4. P.296 –301.